3.60

3.74% -0.14

After Hours: 3.62 0.02 +0.56%

Lantern Pharma Inc (LTRN)

Overview News Price History Option Chain Financials Discussions Forecast

Lantern Pharma Inc stock is traded at $3.60, with a volume of 25,574. It is down -3.74% in the last 24 hours and up +3.45% over the past month. Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.

Previous Close:

$3.74

Open:

$3.74

24h Volume:

25,574

Relative Volume:

0.21

Market Cap:

$40.26M

Revenue:

Net Income/Loss:

$-19.25M

P/E Ratio:

-2.0225

EPS:

-1.78

Net Cash Flow:

$-17.87M

1W Performance:

-4.00%

1M Performance:

+3.45%

6M Performance:

+11.46%

1Y Performance:

-0.83%

1-Day Range:

$3.59

$3.78

1-Week Range:

$3.5178

$4.00

52-Week Range:

$2.55

$6.118

Lantern Pharma Inc Stock (LTRN) Company Profile

Name

Lantern Pharma Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

972-277-1136

Address

1920 MCKINNEY AVENUE, DALLAS, TX

Employee

Twitter

@lanternpharma

Next Earnings Date

2025-08-08

Latest SEC Filings

LTRN's Discussions on Twitter

Compare LTRN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LTRN Lantern Pharma Inc	3.60	41.83M	0	-19.25M	-17.87M	-1.78
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-07-21	Initiated	H.C. Wainwright	Buy

Lantern Pharma Inc Stock (LTRN) Latest News

Dec 10, 2025

Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Daily Commercial

Dec 10, 2025

Dec 05, 2025

Lantern Pharma announces LP-184 clinical trial met all primary endpoints - MSN

Dec 05, 2025

Dec 04, 2025

Lantern Pharma (NASDAQ: LTRN) Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid Tumors - Digital Journal

Dec 04, 2025

Will Lantern Pharma Inc. stock benefit from automationTreasury Yields & AI Forecasted Stock Moves - Newser

Dec 04, 2025

Will Lantern Pharma Inc. stock rally after Fed decisionsPortfolio Return Report & Low Volatility Stock Suggestions - Newser

Dec 04, 2025

Dec 03, 2025

Lantern’s cancer drug LP-184 shows promise in phase 1a trial - Investing.com Australia

Dec 03, 2025

Lantern Pharma advances AI-Driven cancer drug after successful Phase 1a trial - Proactive financial news

Dec 03, 2025

Lantern Pharma (LTRN) Advances with Promising Clinical Insights from Phase 1a Study - GuruFocus

Dec 03, 2025

Lantern Pharma reports additional positive LP-184 Phase 1a results showing durable disease control in heavily pre-treated advanced cancer patients - marketscreener.com

Dec 03, 2025

Lantern’s cancer drug LP-184 shows promise in phase 1a trial By Investing.com - Investing.com South Africa

Dec 03, 2025

Lantern Pharma Reports Positive Phase 1a Data For LP-184 In Advanced Solid Tumors - Nasdaq

Dec 03, 2025